Suzhou Highfine Biotech Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
Suzhou Highfine Biotech has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.4% per year. Suzhou Highfine Biotech's return on equity is 5.2%, and it has net margins of 28.2%.
Wichtige Informationen
9.4%
Wachstumsrate der Gewinne
4.6%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 10.9% |
| Wachstumsrate der Einnahmen | 8.4% |
| Eigenkapitalrendite | 5.2% |
| Netto-Marge | 28.2% |
| Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Suzhou Highfine Biotech Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Sep 24 | 413 | 116 | 42 | 35 |
| 30 Jun 24 | 404 | 106 | 45 | 34 |
| 31 Mar 24 | 355 | 93 | 37 | 34 |
| 31 Dec 23 | 389 | 99 | 36 | 28 |
| 30 Sep 23 | 390 | 105 | 33 | 26 |
| 30 Jun 23 | 387 | 114 | 26 | 21 |
| 31 Mar 23 | 437 | 128 | 26 | 21 |
| 01 Jan 23 | 447 | 129 | 25 | 22 |
| 30 Sep 22 | 465 | 134 | 26 | 21 |
| 30 Jun 22 | 480 | 136 | 29 | 21 |
| 31 Mar 22 | 425 | 124 | 27 | 18 |
| 31 Dec 21 | 369 | 111 | 26 | 15 |
| 31 Dec 20 | 282 | 40 | 50 | 22 |
| 31 Dec 19 | 191 | 58 | 17 | 8 |
| 31 Dec 18 | 142 | 40 | 13 | 7 |
| 30 Sep 18 | 132 | 38 | 11 | 8 |
| 30 Jun 18 | 122 | 31 | 17 | 1 |
| 31 Mar 18 | 108 | 27 | 17 | 0 |
| 31 Dec 17 | 94 | 23 | 9 | 7 |
| 30 Sep 17 | 93 | 22 | 10 | 5 |
| 30 Jun 17 | 93 | 22 | 11 | 3 |
| 31 Mar 17 | 90 | 20 | 13 | 2 |
| 31 Dec 16 | 88 | 19 | 14 | 0 |
| 30 Sep 16 | 82 | 16 | 13 | 0 |
| 30 Jun 16 | 77 | 14 | 13 | 0 |
| 31 Mar 16 | 71 | 12 | 12 | 0 |
| 31 Dec 15 | 66 | 9 | 12 | 0 |
| 31 Dec 14 | 50 | 3 | 9 | 0 |
| 31 Dec 13 | 34 | 2 | 8 | 0 |
Qualität der Erträge: 301393 has high quality earnings.
Wachsende Gewinnspanne: 301393's current net profit margins (28.2%) are higher than last year (26.9%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 301393's earnings have grown by 9.4% per year over the past 5 years.
Beschleunigtes Wachstum: 301393's earnings growth over the past year (10.7%) exceeds its 5-year average (9.4% per year).
Erträge im Vergleich zur Industrie: 301393 earnings growth over the past year (10.7%) exceeded the Pharmaceuticals industry -1.2%.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 301393's Return on Equity (5.2%) is considered low.